1 / 20

GSK-3 In Alzheimer's Disease

GSK-3 In Alzheimer's Disease. pathogenic kinase, biomarker and therapeutic target - bench to bedside in action. Urgent need for translational success. 700,000 people with dementia in the UK over a million with dementia by 2025 financial cost of dementia to the UK is over £17 billion a year.

hachi
Télécharger la présentation

GSK-3 In Alzheimer's Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. GSK-3 In Alzheimer's Disease pathogenic kinase, biomarker and therapeutic target - bench to bedside in action

  2. Urgent need for translational success • 700,000 people with dementia in the UK • over a million with dementia by 2025 • financial cost of dementia to the UK is over £17 billion a year

  3. Accelerating translation through an AHSC • An example of bench to bedside translation • GSK-3 as a biomarker and a therapeutic target in AD • in vitro, cellular models, animal models • biomarker discovery and early clinical trials • Translation in the context of collaborative organisations • three Trusts, one university; many collaborations, numerous disconnects • Accelerated translation • facilitating research • incentivising rapid translation

  4. Amyloid plaques composed of a core of aggregated Ab derived from APP Alzheimer’s pathology • Neurofibrillary tangles composed of aggregated, phosphorylated tau

  5. Environment Genes Amyloid cascade hypothesis

  6. GSK-3 alters tau phosphorylation Tau – no GSK3 • In vitro • Hanger et alNeurosci. Lett. (1992) 147, 58-62 • In non-neuronal cells and neurons • Lovestone et al Curr Biol (1994); 4:1077-1086 • Lovestone et al Neuroscience (1996) 73 1145-1157 • In transgenic mice • Brownlees et al.Neuroreport (1997) 8, 3251-3255 Tau – with GSK3

  7. Environment Genes Amyloid cascade hypothesis GSK-3 • Ab increases GSK-3 activity in neurons • Takashima,A. et al.Neurosci. Res.31, 317-323 (1998) • Ab neurotoxicity is decreased by GSK-3 inhibition • Alvarez,G. et al.FEBS Lett.453, 260-264 (1999)

  8. Wild-type Tau transgenic Geotaxis phenotype 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Days post occlusion Tau over-expression phenotype is GSK-3 dependent • Motor neuron expression of • Tau • Tau + GSK-3b Mudher et al (2004) 9, 522-530

  9. Untreated GSK-3 inhibitor Phenotype GSK-3 inhibition rescues phenotype

  10. Untreated GSK-3 inhibitor GSK-3 inhibition rescues phenotype Phenotype GSK-3 dependent, tau induced phenotype

  11. 170 160 Tet/GSK3 150 wt 140 130 GSK3 inhibited Amplitude EPSP (% baseline) 120 110 100 90 80 70 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 Time (mins) Hooper et al Eur J Neurosci (2007); 25: 81-86. GSK-3 regulates memory and plasticity • Increased expression of GSK3 in mouse brain: • Increased tau phosphorylation • Deficits in learning and memory • Lucas et al, EMBO J. 2001;20:27-39

  12. Amyloid cascade hypothesis GSK3 cascade hypothesis GSK3 regulation ie diabetes GSK-3 Genes associated with GSK3 regulation

  13. ** ** **P<0.01 GSK-3 as a biomarker for AD • Increase in GSK-3 protein in AD and in MCI in white blood cells • Hye,A. et al.Neurosci. Lett.373, 1-4 (2005)

  14. GSK-3 inhibition as a therapeutic strategy • Lithium is an inhibitor of GSK-3 • In neurons and at therapeutic doses Non- phosphorylated tau (ie normal) Phosphorylated tau (ie AD like) Lovestone et al Biol Psychiatry 1999; 45:995-1003 Leroy et al. FEBS Lett 2000; 465:34-38

  15. GSK-3 inhibition as a therapeutic strategy • Lithium is a safe and feasible treatment in AD • One year, MRC sponsored trial • Macdonald et al. Int J Geriatr Psychiatry 2008; 23:704-711. • Lithium trials underway in multiple neurodegenerative diseases • Specific GSK3 inhibitors in Phase II clinical trials in AD

  16. Conclusions • Therapeutic target • Tau kinase induced by Ab • Mice and Drosophila models show reversible AD-relevant phenotypes • Environmental and genetic evidence aetiologies involving dysregulation of GSK3 in AD • Potential biomarker • Altered in blood cells in AD • IP retained by KHP and exploitation plans underway • Therapeutic trials underway • Lithium in AD and other neurodegenerative diseases • Specific GSK3 inhibitors in AD trials

  17. KCL BRC Mental Health Target identification Early trials/ Experimental medicine Biomarker discovery Efficacy trials KCH, SLaM, GSTT, others SLaM Translational pathway – GSK3 and AD

  18. KCL BRC Mental Health Dementia and mental health in later life CAG Target identification Early trials/ Experimental medicine Biomarker discovery Efficacy trials Bench Bedside HSR & Innovation KCH, SLaM, GSTT, others SLaM BSI BRC-MH Translational pathway – GSK3 and AD

  19. Accelerating translation in the context of the AHSC • Closer collaboration between basic and clinical sciences • CAG structure enables and incentivises collaboration • e.g. lithium clinics and biomarkers of GSK3 activity via BRC-MH • Closer collaboration between basic sciences • basic science technologies ‘disease blind’ • e.g. GSK3 signalling in development and in differentiation in the BSI • Enhanced recruitment to clinical studies • use of IT based recruitment ; research as a mission within the NHS • e.g. 3000 referrals to MHOA / year accessed through CRIS and BRC-MH • More effective experimental medicine • complex interventions • e.g. bed stays, EEG, lumbar puncture via the CRF and BRC-MH • Rapid translation of research advances • CAG structure enables and incentivises translation • e.g. early detection, early intervention through memory services

  20. Acknowledgements • Current lab members and colleagues • Richard Killick • Claudie Hooper • Rena Meimaridou • Graham Cocks • Mirsada Causevic • Madhav Thambisetty • Anna Kinsey • Petra Proitsi • John Powell • John Stephenson • Brian Anderton • Funders • Wellcome Trust • Alzheimer’s Research Trust • Alzheimer’s Society • Medical Research Council

More Related